Downregulation of microRNA-382 is associated with poor outcome of esophageal squamous cell carcinoma

Figure 1 Amplification plot with ΔCt values of miR-382 in all patients.

Figure 2 miR-382 expression levels were associated with outcomes of esophageal squamous cell carcinoma patients. A: The esophageal squamous cell carcinoma (ESCC) patients with good outcome generally exhibited higher miR-382 expression than those with poor outcome (^aP < 0.05, good outcome vs poor outcome); B: Stage I ESCC patients with good outcome exhibited higher levels of miR-382 than those with poor prognosis (^aP < 0.05, good outcome vs poor outcome); C: Stage II ESCC with good outcome exhibited higher levels of miR-382 than those with poor outcome (^aP < 0.05, good outcome vs poor outcome); D: Stage III ESCC with good outcome exhibited higher levels of miR-382 than those with poor outcome (^aP < 0.05, good outcome vs poor outcome).

Figure 3 miR-382 expression levels were reverse-correlated with esophageal squamous cell carcinoma patient survival times. A: The esophageal squamous cell carcinoma (ESCC) with higher miR-382 expression generally exhibited longer survival times, compared to those with lower expression levels (P < 0.001, higher vs lower miR-382 level); B: Stage I ESCC patients with higher levels of miR-382 exhibited longer survival times, compared to those with lower expression levels (P < 0.01, higher vs lower miR-382 level); C: Stage II ESCC patients with higher levels of miR-382 exhibited longer survival times, compared to those with lower expression levels (P < 0.01, higher vs lower miR-382 level); D: Stage III ESCC patients with higher levels of miR-382 exhibited longer survival times, compared to those with lower expression levels (P < 0.01, higher vs lower miR-382 level).